Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of JTE-013 in preparation of medicine for protecting glaucoma optic nerve injury

A technology for optic nerve injury and glaucoma, which is applied in the field of biomedicine and can solve problems such as poor specificity and disease deterioration.

Pending Publication Date: 2022-07-29
ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

"Fingolimod" and "Sinimod" have been approved by the FDA for the treatment of multiple sclerosis with typical manifestations of inflammatory demyelination. Poor, it will cause more adverse reactions, and there are risks such as deterioration of the condition after stopping the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of JTE-013 in preparation of medicine for protecting glaucoma optic nerve injury
  • Application of JTE-013 in preparation of medicine for protecting glaucoma optic nerve injury
  • Application of JTE-013 in preparation of medicine for protecting glaucoma optic nerve injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] 1. Drug preparation: Purchase drug JTE-013 (Tocris, CatNo.2392), according to the instructions, dissolve the powder in DMSO to make a 100mM stock solution, store it in a -80°C refrigerator, and dilute it with PBS to a working solution of the required concentration. , now with the current use. Pre-experimental exploration was carried out with JTE-013 at concentrations of 100 μM, 300 μM, 900 μM, 1800 μM and 2700 μM, respectively, and it was found that the concentration of 900 μM had the best optic nerve protection effect.

[0024] 2. Intravitreal injection:

[0025] (1) 5-8 week old male C57 / B6J mice were purchased and reared adaptively for 7 days to start the experiment. The left eye was the experimental eye, and the right eye was the parallel control eye. Divided into 3 large groups, each large group of 5 groups, each group of 10. Including: normal control group (Control, Ctrl in the figure), I / R modeling group (I / R+PBS, I / R+PBS or PBS in the figure), I / R+JTE-013 tre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of JTE-013 in preparation of a medicine for protecting glaucoma optic nerve injury. According to the application, the JTE-013 is applied to treatment of an ischemia reperfusion model of a glaucoma related animal model for the first time, the treatment effect of the JTE-013 is determined, and the JTE-013 can obviously improve retinal ganglion cell injury caused by increase of intraocular pressure; axonal injury caused by increase of intraocular pressure can be obviously improved; the activation of microglial cells can be obviously inhibited; myelin sheath regeneration and proliferation of myelin sheath formation cell oligodendroglia cells can be obviously promoted; the visual function can be obviously recovered.

Description

Technical areas: [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of JTE-013 in preparing drugs for protecting optic nerve damage caused by glaucoma. Background technique: [0002] Glaucoma is a neurodegenerative disease characterized by progressive damage to retinal ganglion cells (RGCs) and their axons. Typical clinical manifestations include optic atrophy, visual field defects, and vision loss. Although the pathogenesis of glaucoma has been extensively studied, it is still not fully understood. At present, lowering intraocular pressure is still considered the only effective method to treat glaucoma. However, lowering intraocular pressure through drugs or surgery cannot reverse optic nerve damage and restore visual function. How to effectively protect RGCs and promote axon regeneration and functional recovery is the focus of basic research. Studies have shown that demyelination usually occurs after axonal injury, and r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/444A61P27/06A61P25/00A61P27/02
CPCA61K31/444A61P27/06A61P25/00A61P27/02
Inventor 卓业鸿李轶擎薛京菲刘哲林记城
Owner ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com